Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

30 Apr 2013

Abstract excerpt

OBJECTIVES: It has long been assumed that some rifampicin-resistant Mycobacterium tuberculosis strains are susceptible to, and thus treatable with, rifabutin. However, clinical breakpoints for susceptibility testing of rifabutin as well as the evidence for a clinical effect of rifabutin in rifampicin-resistant strains remains poorly defined. The objective of this study was to re-evaluate the breakpoint for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Diseases and Tuberculosis
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23633684
DOI: 10.1093/jac/dkt150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?PMID 23633684Read ↗

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes.Semantic proximity Read ↗

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosisSemantic proximity Read ↗

Discordance in Genotypic and Phenotypic anti-tuberculosis drug susceptibility results: time to reconsider critical concentrationSemantic proximity Read ↗

Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicinSemantic proximity Read ↗

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones inMycobacterium tuberculosisSemantic proximity Read ↗

The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.Semantic proximity Read ↗

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteriaSemantic proximity Read ↗

Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.Semantic proximity Read ↗

[Determination of genetic mutations in rpoB of the isolates of Mycobacterium tuberculosis complex those susceptibilities to rifampicin were interpreted as indeterminate by BrothMIC MTB].Semantic proximity Read ↗

Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria.Semantic proximity Read ↗

Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category.Semantic proximity Read ↗

Minimum inhibitory concentration distributions for Mycobacterium avium complex—towards evidence-based susceptibility breakpointsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.